Interleukin-2 in the treatment of renal cancerMARGOLIN, K. A.Seminars in oncology. 2000, Vol 27, Num 2, pp 194-203, issn 0093-7754Article

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma : A southwest oncology group studyMARGOLIN, K. A; LIU, P.-Y; FLAHERTY, L. E et al.Journal of clinical oncology. 1998, Vol 16, Num 2, pp 664-669, issn 0732-183XArticle

Cellular immunotherapy and autologous transplantation for hematologic malignancyMARGOLIN, K. A; NEGRIN, R. S; WONG, K. K et al.Immunological reviews. 1997, Vol 157, pp 231-240, issn 0105-2896Article

Effect of low-dose prophylactic dopamine on high-dose cisplatin, induced electrolyte wasting, ototoxicity, and epidermal growth factor excretion : a randomized, placebo-controlled, double-blind trialSOMLO, G; DOROSHOW, J. H; HAMASAKI, V. K et al.Journal of clinical oncology. 1995, Vol 13, Num 5, pp 1231-1237, issn 0732-183XArticle

High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancerSOMLO, G; DOROSHOW, J. H; FORMAN, S. J et al.Cancer. 1994, Vol 73, Num 1, pp 125-134, issn 0008-543XArticle

In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remissionSTEIN, A. S; O'DONNELL, M. R; SPIELBERGER, R et al.Journal of clinical oncology. 1996, Vol 14, Num 8, pp 2206-2216, issn 0732-183XArticle

A phase II clinical trial of interleukin-2 and lymphokine-activated killer cells in advanced colorectal carcinomaHAWKINS, M. J; ATKINS, M. B; GAYNOR, E. R et al.Journal of immunotherapy. 1994, Vol 15, Num 1, pp 74-78, issn 1053-8550Article

Phase I trial of interleukin-2 plus doxorubicinMARGOLIN, K. A; DOROSHOW, J. H; CALIENDO, G et al.Journal of immunotherapy. 1993, Vol 14, Num 1, pp 70-76, issn 1053-8550Article

Effective initial therapy of advanced breast cancer wit fluorouracil and high-dose, continuous infusion calcium leucovorinMARGOLIN, K. A; DOROSHOW, J. H; AKMAN, S. A et al.Journal of clinical oncology. 1992, Vol 10, Num 8, pp 1278-1283, issn 0732-183XArticle

Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cellsMARGOLIN, K. A; WRIGHT, C; FORMAN, S. J et al.Leukemia. 1997, Vol 11, Num 5, pp 723-728, issn 0887-6924Article

Phase II trial of biochemotherapy with interferon α, dacarbazine, cisplatin and tamoxifen in metastatic melanoma : a southwest oncology group trialMARGOLIN, K. A; LIU, P. Y; WEISS, G. R et al.Journal of cancer research and clinical oncology. 1999, Vol 125, Num 5, pp 292-296, issn 0171-5216Article

Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumorsNEWMAN, E. M; CARROLL, M; SHIBATA, S et al.Cancer chemotherapy and pharmacology. 1997, Vol 39, Num 3, pp 254-258, issn 0344-5704Article

High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease : results in 85 patients with analysis of prognostic factorsAUAYPORN NADEMANEE; O'DONNELL, M. R; MARGOLIN, K. A et al.Blood. 1995, Vol 85, Num 5, pp 1381-1390, issn 0006-4971Article

Phase II trial of cisplatin and α-interferon in advanced malignant melanomaMARGOLIN, K. A; DOROSHOW, J. H; AKMAN, S. A et al.Journal of clinical oncology. 1992, Vol 10, Num 10, pp 1574-1578, issn 0732-183XArticle

Phase II trial of high-dose interleukin-2 and lymphokine-activated killer cells in Hodgkin's disease and non-Hodgkin's lymphomaMARGOLIN, K. A; ARONSON, F. R; MIER, J. W et al.Journal of immunotherapy. 1991, Vol 10, Num 3, pp 214-220, issn 1053-8550, 7 p.Article

Sixteen-week multidrug regimen versus cyclophosphamide, doxorubicin, and fluorouracil as adjuvant therapy for node-positive, receptor-negative Breast cancer : An Intergroup studyFETTING, J. H; GRAY, R; HENDERSON, I. C et al.Journal of clinical oncology. 1998, Vol 16, Num 7, pp 2382-2391, issn 0732-183XArticle

Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors : a southwest oncology group studyRINEHART, J; MARGOLIN, K. A; TRIOZZI, P et al.Clinical cancer research. 1995, Vol 1, Num 10, pp 1139-1144, issn 1078-0432Article

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinomaWEISS, G. R; MARGOLIN, K. A; HAWKINS, M. J et al.Journal of clinical oncology. 1992, Vol 10, Num 2, pp 275-281, issn 0732-183XArticle

Phase I trial of interleukin-2 plus gamma-interferonMARGOLIN, K. A; DOROSHOW, J. H; AKMAN, S. A et al.Journal of immunotherapy. 1992, Vol 11, Num 1, pp 50-55, issn 1053-8550Article

Phase I study of high-dose continuous-infusion recombinant interleukin-2 and autologous lymphokine-activated killer cells in patients with metastatic or unresectable malignant melanoma and renal cell carcinomaGAYNOR, E. R; WEISS, G. R; BAR, M. H et al.Journal of the National Cancer Institute. 1990, Vol 82, Num 17, pp 1397-1402, issn 0027-8874Article

High-dose cytosine arabinoside and daunorubicin induction therapy for adult patients with de novo non m3 acute myelogenous leukemia : impact of cytogenetics on achieving a complete remissionSTEIN, A. S; O'DONNELL, M. R; MARGOLIN, K. A et al.Leukemia. 2000, Vol 14, Num 7, pp 1191-1196, issn 0887-6924Article

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients : Reversible dose-limiting neurological toxicitySOSMAN, J. A; ARONSON, F. R; MIER, J et al.Clinical cancer research. 1997, Vol 3, Num 1, pp 39-46, issn 1078-0432Article

High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell reinfusion in patients with metastatic or high-risk primary breast cancerSOMLO, G; DOROSHOW, J. H; HARRISON, J et al.Cancer. 1994, Vol 73, Num 6, pp 1678-1685, issn 0008-543XArticle

Phase II trial of 5-fluorouracil and high-dose folinic acid as first- or second-line therapy for advanced breast cancerMARGOLIN, K. A; GREEN, S; UPCHURCH, C et al.American journal of clinical oncology. 1994, Vol 17, Num 2, pp 175-180, issn 0277-3732Article

Phase IB clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma : clinical and immunologic effectsSOSMAN, J. A; WEISS, G. R; ERNEST, M. L et al.Journal of clinical oncology. 1993, Vol 11, Num 8, pp 1496-1505, issn 0732-183XArticle